Decursin inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic retinopathy via VEGFR2

Molecular and Cellular Endocrinology

Volumn 378, Issue 1-2, 2013, Pages 46-52

  Yang, Ying ^a,c,f   Yang, Ke ^b   Li, Yiping ^a   Li, Xianli ^a   Sun, Qiangming ^d   Meng, Hua ^b   Zeng, Ying ^e   Hu, Yong ^e   Zhang, Ying ^a  

^a Yunnan Province 2nd Hospital   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c University of Missouri   (United States)

^d INSTITUTE OF MEDICAL BIOLOGY   (China)

^e TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^f YUNNAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Decursin; Diabetic retinopathy; Proliferation; VEGFR 2

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; BROXURIDINE; DECURSIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA CELL; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS; DECURSIN; DIABETIC RETINOPATHY; PROLIFERATION; VEGFR-2;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOPYRANS; BUTYRATES; CELL PROLIFERATION; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84884414793     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.04.021     Document Type: Article

References (35)

1. Ahn K.S., Sim W.S., Kim I.H. Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Planta Med. 1996, 62:7-9.
2. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl. J. Med. 1994, 331:1480-1487.
3. Boulton M., Foreman D., Williams G., McLeod D. VEGF localisation in diabetic retinopathy. Br. J. Ophthalmol. 1998, 82:561-568.
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
5. Cheung N., Wang J.J., Klein R., Couper D.J., Sharrett A.R., Wong T.Y. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis risk in communities study. Diabetes Care 2007, 30:1742-1746.
6. Choi S.S., Han K.J., Lee H.K., Han E.J., Suh H.W. Antinociceptive profiles of crude extract from roots of Angelica gigas NAKAI in various pain models. Biol. Pharm. Bull. 2003, 26:1283-1288.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25(4):581-611.
8. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005, 94:209-231.
9. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
10. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9(6):669-676.
11. Fowler M. Microvascular and macrovascular complications of diabetes. Clin. Diabetes 2008, 26:77-82.
12. Gardner T.W., Lieth E., Khin S.A., Barber A.J., Bonsall D.J., Lesher T., Rice K., Brennan W.A. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 1997, 38:2423-2427.
13. Gariano R.F., Gardner T.W. Retinal angiogenesis in development and disease. Nature 2005, 438:960-966.
14. Hayden M.R., Sowers K.M., Pulakat L., Joginpally T., Krueger B., Whaley-Connell A., Sowers J.R. Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and Type 2 diabetes mellitus. Cardiorenal Med. 2011, 1:193-210.
15. Hirase K., Ikeda T., Sotozono C., Nishida K., Sawa H., Kinoshita S. Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy. Arch. Ophthalmol. 1998, 116:738-741.
16. Jung M.H., Lee S.H., Ahn E.M., Lee Y.M. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 2009, 30:655-661.
17. Kim J.H., Kim J.H., Lee Y.M., Ahn E.M., Kim K.W., Yu Y.S. Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation. Mol. Vis. 2009, 12:1868-1875.
18. Klein R., Marino E.K., Kuller L.H., Polak J.F., Tracy R.P., Gottdiener J.S., Burke G.L., Hubbard L.D., Boineau R. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. Br. J. Ophthalmol. 2002, 86:84-90.
19. Lee J.H., Choi S., Lee Y., Lee H.J., Kim K.H., Ahn K.S., Bae H., Lee H.J., Lee E.O., Ahn K.S., Ryu S.Y., Lü J., Kim S.H. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades. Mol. Cancer Ther. 2010, 9:389-399.
20. Lu M., Kuroki M., Amano S., Tolentino M., Keough K., et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest. 1998, 101:1219-1224.
21. Mahat B., Chae J.W., Baek I.H., Song G.Y., Song J.S., Cho S.K., Kwon K.I. Physicochemical characterization and toxicity of decursin and their derivatives from Angelica gigas. Biol. Pharm. Bull. 2012, 35:1084-1090.
22. Mahat, B., Chae, J.W., Baek, I.H., Song, G.Y., Song, J.S., Ma, J.Y., Kwon, K.I., 2012. Biopharmaceutical characterization of decursin and their derivatives for drug discovery. Drug Dev Ind Pharm. September 25, 2012 (Epub ahead of print).
23. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5(Suppl. 1):3-10.
24. Patel S., Santani D. Role of NF-kappa B in the pathogenesis of diabetes and its associated complications. Pharmacol. Rep. 2009, 61:595-603.
25. Qaum T., Xu Q., Joussen A.M., Clemens M.W., Qin W., Miyamoto K., Hassessian H., Wiegand S.J., Rudge J., Yancopoulos G.D., Adamis A.P. VEGF-initiated blood-retinal barrier breakdown in diabetes. Invest. Ophthalmol. Vis. Sci. 2001, 42:2408-2413.
26. Rudge J.S., Thurston G., Davis S., Papadopoulos N., Gale N., Wiegand S.J., Yancopoulos G.D. VEGF trap as a novel anti-angiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets. Cold Spring Harbor Sym. Quant. Biol. 2005, 70:411-418.
27. Sarker S.D., Nahar L. Natural medicine: the genus Angelica. Curr. Med. Chem. 2004, 11:1479-1500.
28. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell. Struct. Funct. 2001, 26:25-35.
29. Simo R., Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008, 51:1574-1580.
30. Stone J., Itin A., Alon T., Pe'er J., Gnessin H., Chan-Ling T., Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 1995, 15:4738-4747.
31. Valiatti F.B., Crispim D., Benfica C., Valiatti B.B., Kramer C.K., Canani L.H. The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy. Arq. Bras. Endocrinol. Metabol. 2011, 55:106-113.
32. Yang Y., Andresen B.T., Yang K., Zhang Y., Li X., Wang H. Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp. Biol. Med. (Maywood) 2010, 235:1204-1211.
33. Yang Y., Hayden M.R., Sowers S., Bagree S.V., Sowers J.R. Retinal redox stress and remodeling in cardiometabolic syndrome and diabetes. Oxid. Med. Cell. Longev 2010, 3:392-403.
34. Ying Y., Yang K., Liu Y., Chen Q.J., Shen W.F., et al. A uremic solute, P-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway. Circ. J. 2011, 75:2252-2259.
35. WHO. Diabetes fact sheet. 2011 [cited 10/01/12]. <>. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.